Key result
Impella support in anterior STEMI is linked to a ~10% absolute LVEF increase among survivors.
Why the study?
The evolution of cardiac function and dimensions beyond hospital discharge remains uncertain in patients with anterior STEMI and overt cardiogenic shock receiving LV unloading via an Impella pump.
Cohort (n=66)
p-value: p=<0.0001
In patients with acute anterior STEMI treated with an Impella device, survivors demonstrated a significant improvement in left ventricular ejection fraction at outpatient follow-up without evidence of adverse remodeling.
Hypothesis-generating for Impella in anterior STEMI survivors; leaves open whether benefits outweigh risks in randomized trials.
BackgroundLeft ventricular (LV) unloading via the percutaneous micro-axial Impella pump is increasingly used in patients with anterior ST-segment elevation myocardial infarction (STEMI) and overt cardiogenic shock. In this context, the evolution of cardiac function and dimensions beyond hospital discharge remains uncertain. We aimed to characterize echocardiographic changes over time in patients with acute anterior STEMI treated with an Impella device.MethodsFrom an ongoing prospective registry, consecutive patients with acute anterior STEMI managed with an Impella device were extracted. Transthoracic echocardiography was performed at index hospitalization and at first outpatient follow-up. Predictors of response, defined as a ≥ 10% absolute increase in left ventricular ejection fraction (LVEF) at follow-up, were sought.ResultsA total of 66 patients (89.4% male, aged 64.3 ± 11.6 years) with anterior STEMI were treated with an Impella device in the first 24 hours of hospitalization, from 2014 to 2022. In-hospital mortality was 24%. Major bleeding and vascular complications requiring surgery occurred in 24% and 11% of patients, respectively. At baseline, mean LVEF was 34% ±12%. At follow-up, survivors showed a significant increase in LVEF (P < 0.0001), whereas LV dimensions, diastolic parameters, and measures of right ventricular dimension and function remained stable. Overall, 28 patients had a ≥ 10% absolute increase in LVEF at follow-up. Baseline creatinine was the only significant predictor of response at univariate analysis.ConclusionsAmong patients with anterior STEMI requiring mechanical hemodynamic support with an Impella device, the majority of survivors showed a sustained increase in LV function, without evidence of adverse remodelling. This signal warrants further investigation in dedicated trials.
No takes yet. Share an insight, caveat, or question.
Tersalvi et al. (2022) conducted a cohort in Acute anterior ST-elevation myocardial infarction (STEMI) (n=66). Impella device was evaluated on ≥ 10% absolute increase in left ventricular ejection fraction (LVEF) at follow-up (p=<0.0001). Impella device support in patients with anterior STEMI was associated with a significant increase in LVEF among survivors at follow-up (P<0.0001), with 28 patients achieving a ≥10% absolute increase.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: